Close

Welcome back to Stockhouse
Member Sign In

Email or Username:
Password:
Close

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Enter your email address:
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
×

Get our Best Content in Your Email

You are already a member! Please enter your password to sign in.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Insiders  |  Valuation

ProMetic Life Sciences Inc. T.PLI

Sector: Healthcare | Sub-Sector: Biotechnology
Alternate Symbol(s):  PFSCF

"ProMetic Life Sciences Inc is a biopharmaceutical company. The Company is engaged in bioseparations, plasma-derived therapeutics and small-molecule drug development."

Latest News

ProMetic's plasminogen granted Fast Track designation by the US FDA

Canada NewsWire June 13, 2016

ProMetic to present new data on how PBI-4050 keeps pancreatic beta cells alive at the American Diabetic Association's upcoming annual meeting

Canada NewsWire June 9, 2016

ProMetic announces closing of $60 million bought deal offering of common shares

Canada NewsWire May 25, 2016

Health Canada authorizes ProMetic to proceed with its PBI-4050 clinical trial in patients with cystic fibrosis

Canada NewsWire May 18, 2016

ProMetic Reports its First Quarter 2016 Highlights and Financial Results

Canada NewsWire May 12, 2016

Positive response in kidney and urinary tract to ProMetic's plasminogen treatment in a plasminogen deficient patient under an expanded access (compassionate use) protocol in the USA

Canada NewsWire May 11, 2016

Prometic announces successful treatment of a plasminogen-deficient patient under an expanded access (compassionate use) protocol in the USA

PR Newswire May 3, 2016

INVESCO INVESTMENT TRUSTS - Portfolio Disclosure

PR Newswire UK Disclosure May 3, 2016

ProMetic's PBI-4050: efficacy further evidenced in type 2 diabetic and metabolic syndrome clinical trial

Canada NewsWire April 26, 2016

ProMetic confirms PBI-4050's Anti-Fibrotic Effect in Nash Model and on Human Hepatic Stellate Cells

Canada NewsWire April 14, 2016

ProMetic reports its 2015 fourth quarter and year end highlights and financial results

Canada NewsWire March 30, 2016

ProMetic confirms PBI-4050's positive effects on novel biomarkers in patients suffering from metabolic syndrome and Type 2 diabetes

Canada NewsWire March 22, 2016

ProMetic to report its fourth quarter and year end 2015 financial results and hold conference call / webcast

Canada NewsWire March 21, 2016

ProMetic announces the addition of scleroderma to PBI-4050's targeted indications

Canada NewsWire March 15, 2016

ProMetic secures $30 million follow-on financing from Structured Alpha LP, an affiliate of Thomvest Asset Management Inc.

Canada NewsWire March 1, 2016

OTC Markets Group Announces the 2016 OTCQX Best 50

Stockhouse Editorial February 17, 2016

ProMetic Provides 2016 Milestones Outlook at BIO-CEO Conference in New York

Canada NewsWire February 9, 2016

Prometic Provides Revenue Guidance Update

Canada NewsWire December 17, 2015

Prometic's PBI-4050 To Target Cystic Fibrosis As Its Next Orphan Indication

Canada NewsWire December 14, 2015

ProMetic to disclose new PBI-4050 orphan indication and hold conference call / webcast

Canada NewsWire December 11, 2015
Read more ››